BSE Live
Sep 05, 16:01Prev. Close
959.95
Open Price
958.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Sep 05, 15:49Prev. Close
960.10
Open Price
959.30
Bid Price (Qty.)
946.50 (114)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 5,900.95 | 5,757.55 | 5,003.13 | 4,987.49 | 4,934.86 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 5,900.95 | 5,757.55 | 5,003.13 | 4,987.49 | 4,934.86 | |
Total Operating Revenues | 6,032.63 | 5,874.06 | 5,149.00 | 5,035.41 | 5,051.44 | |
Other Income | 47.88 | 31.32 | 3.54 | 51.14 | 9.73 | |
Total Revenue | 6,080.51 | 5,905.38 | 5,152.54 | 5,086.55 | 5,061.17 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 1,672.17 | 1,403.01 | 1,250.08 | 1,129.11 | 1,175.71 | |
Purchase Of Stock-In Trade | 385.14 | 449.70 | 337.21 | 353.25 | 279.33 | |
Operating And Direct Expenses | 0.00 | 0.00 | 31.02 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -268.54 | -52.36 | 72.84 | 19.87 | -157.13 | |
Employee Benefit Expenses | 1,466.57 | 1,335.91 | 1,094.82 | 1,062.30 | 948.27 | |
Finance Costs | 76.47 | 54.47 | 49.00 | 17.02 | 12.77 | |
Depreciation And Amortisation Expenses | 277.08 | 271.14 | 272.95 | 284.92 | 152.60 | |
Other Expenses | 1,875.90 | 1,739.28 | 1,698.68 | 1,562.08 | 1,233.03 | |
Total Expenses | 5,484.79 | 5,201.15 | 4,806.60 | 4,428.55 | 3,644.58 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 595.72 | 704.23 | 345.94 | 658.00 | 1,416.59 | |
Exceptional Items | 12.87 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 608.59 | 704.23 | 345.94 | 658.00 | 1,416.59 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 105.98 | 41.50 | 0.00 | 115.70 | 241.20 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Tax For Earlier Years | -0.51 | -3.75 | -0.79 | -1.25 | 0.00 | |
Total Tax Expenses | 105.47 | 37.75 | -0.79 | 114.45 | 241.20 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 503.12 | 666.48 | 346.73 | 543.55 | 1,175.39 | |
Profit/Loss From Continuing Operations | 503.12 | 666.48 | 346.73 | 543.55 | 1,175.39 | |
Profit/Loss For The Period | 503.12 | 666.48 | 346.73 | 543.55 | 1,175.39 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 25.60 | 33.91 | 17.64 | 27.65 | 60.67 | |
Diluted EPS (Rs.) | 25.60 | 33.91 | 17.64 | 27.65 | 60.67 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 216.22 | 157.25 | 196.56 | 275.19 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 550.00 | 550.00 | 400.00 | 500.00 | 700.00 |
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
06.05.2025
Alembic Pharma Consolidated March 2025 Net Sales at Rs 1,769.64 crore, up 16.66% Y-o-Y
06.05.2025
Alembic Pharma Standalone March 2025 Net Sales at Rs 1,570.64 crore, up 6.52% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct